RMD - ResMed Inc

RMD - ResMed Inc

https://www.resmed.co.in

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Here's Why ResMed ( RMD ) is a Strong Growth Stock

Zacks Commentary • 3 days, 2 hours ago • score: 0.39

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority

GlobeNewswire • 1 week, 4 days ago • score: 0.57

New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care ...

Here's Why ResMed ( RMD ) is a Strong Growth Stock

Zacks Commentary • 2 weeks, 5 days ago • score: 0.41

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

GlobeNewswire • 2 weeks, 5 days ago • score: 0.40

Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among ...

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

GlobeNewswire • 3 weeks, 6 days ago • score: 0.71

SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Resmed ( NYSE: RMD, ASX: RMD ) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, ...

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio - ResMed ( NYSE:RMD )

Benzinga • 3 weeks, 6 days ago • score: 0.63

Mowad-Nassar is Senior Vice President at AbbVie and President, Specialty and U.S. Therapeutics Operations Her appointment brings over 30 years of strategic, commercial, and operational expertise in the pharmaceutical and broader healthcare industry, with a focus on digital innovation

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

52W High

$293.81

52W Low

$199.07

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.85

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

29.16

Forward P/E (<15 better)

25.97

EV/EBITDA (<8 favorable)

20.91

EV/Revenue (<3 favorable)

7.81

P/S (TTM) (<3 favorable)

7.88

P/B (<3 favorable)

6.80

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

0.79%

Institutions (25–75% balanced)

64.75%

Shares Outstanding

146,415,000

Float

145,482,000

Dividend Yield (2–6% sweet spot)

0.01%

Ex‑Dividend Date

2025-08-14

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

5,146,327,000

Gross Profit (TTM)

3,087,086,000

EPS (TTM)

9.50

Profit Margin (>10% good)

0.27%

Operating Margin (TTM) (higher better)

0.34%

ROE (TTM) (>15% strong)

0.26%

EPS YoY (Quarterly) (>10% good)

0.30

Revenue YoY (Quarterly) (>8% good)

0.10

Momentum

Bearish momentum

Value

-1.6278

Previous

-1.0501

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025